MaxCyte, Inc. Grant of Options (9370E)
15 February 2018 - 6:01PM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 9370E
MaxCyte, Inc.
15 February 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Maryland, USA, 15 February 2018 - MaxCyte (LSE: MXCT, MXCR) the
global cell-based medicines and technology company, announces that
it granted options, effective February 12, 2018, over a total of
40,900 options of its common stock in the Company ("Common Stock")
to Richard Douglas, Non-Executive Director of the Company ("Option
Grant").
The Option Grant vests ratably on a monthly basis following
grant over 48 months. The Option Grant has an exercise period of 10
years from date of grant, at which time they will expire. The
Option Grant is effective February 12, 2018, at an exercise price
of 251.00p per option.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial
responsibilities/person closely associated
==== =====================================================================
a) Name Richard Douglas
==== ================================ ===================================
2 Reason for the notification
==== =====================================================================
a) Position/status Non-Executive Director and PDMR
==== ================================ ===================================
b) Initial notification/Amendment Initial notification
==== ================================ ===================================
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
==== =====================================================================
a) Name MaxCyte, Inc.
==== ================================ ===================================
b) LEI 54930053YHXULRFCU991
==== ================================ ===================================
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
==== =====================================================================
a) Description Grant of options over Share
of the financial of Common Stock
instrument,
type of instrument
==== ================================ ===================================
b) Identification US57777K1060
Code
==== ================================ ===================================
c) Nature of Grant of options to a PDMR
the transaction
==== ================================ ===================================
d) Price(s) and Price(s) Volume(s)
volume(s)
==== ================================ ==================== =============
251.00 pence 40,900
========================================================== =============
e) Aggregated N/A (Single transaction)
information
- Aggregated
volume
- Price
==== ================================ ===================================
f) Date of the 12 February 2018
transaction
==== ================================ ===================================
g) Place of the Outside a trading venue
transaction
==== ================================ ===================================
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Suki Virji
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving
the acceleration of the discovery, development, manufacturing and
commercialization of next-generation, cell-based medicines. The
Company provides its patented, high-performance cell engineering
enabling technology to biopharmaceutical partners engaged in drug
discovery and development, biomanufacturing, and cell therapy,
including gene editing and immuno-oncology. With its robust
delivery technology, MaxCyte's team of scientific experts helps its
partners to unlock their product potential and solve problems. This
technology allows for the engineering of nearly all cell types,
including human primary cells, with any molecule, at any scale. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large-scale, clinical and
commercial grade cell engineering in a non-viral system and with
low-toxicity concerns. The Company's cell-engineering enabling
technology is FDA-accredited, providing MaxCyte's customers and
partners with an established regulatory path to commercialize
cell-based medicines. MaxCyte is also developing CARMA, its
proprietary, breakthrough platform in immuno-oncology, to rapidly
manufacture CAR therapies for a broad range of cancer indications,
including solid
tumours where existing CAR-T approaches face significant challenges. For more information, visit http://www.maxcyte.com/.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAFALFLPPEAF
(END) Dow Jones Newswires
February 15, 2018 02:01 ET (07:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024